Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation
Merkel cell carcinoma (MCC) is a rare cutaneous tumour with neuroendocrine differentiation. Metastasis occurs preferentially to regional lymph nodes but distant and multiple visceral metastases may occur. Chemotherapy has been performed with a variety of protocols based largely on agents active in s...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2000]
|
| In: |
British journal of dermatology
Year: 2000, Volume: 143, Issue: 4, Pages: 837-839 |
| ISSN: | 1365-2133 |
| DOI: | 10.1046/j.1365-2133.2000.03852.x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1046/j.1365-2133.2000.03852.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2133.2000.03852.x 
|
| Author Notes: | V. Waldmann, H. Goldschmidt, A. Jäckel, M. Deichmann, U. Hegenbart, W. Hartschuh, A. Ho and H. Näher |
| Summary: | Merkel cell carcinoma (MCC) is a rare cutaneous tumour with neuroendocrine differentiation. Metastasis occurs preferentially to regional lymph nodes but distant and multiple visceral metastases may occur. Chemotherapy has been performed with a variety of protocols based largely on agents active in small-cell lung cancer. Owing to the rarity of MCC, there is no standard protocol for the treatment of metastatic disease. We report a 59-year-old patient with systemic metastatic MCC. After diagnosis of distant metastases, first-line polychemotherapy (cisplatin 80 mg m−2, doxorubicin 50 mg m−2, etoposide 300 mg m−2 and bleomycin 30 mg) was administered four times at 3-weekly intervals and resulted in partial remission of metastases. Subsequently, high-dose chemotherapy according to the PEI regimen (ifosfamide 12 g m−2, carboplatin 900 mg m−2 and etoposide 1500 mg m−2) was applied, followed by autologous blood stem cell transplantation (ABSCT). This protocol resulted in a complete remission that lasted for 6 months. This is the first report on a complete remission of metastatic MCC after high-dose polychemotherapy and ABSCT. High-dose chemotherapy might be a therapeutic option in chemosensitive metastatic MCC, and further evaluation is warranted. |
|---|---|
| Item Description: | Elektronische Reproduktion der Druckausgabe Gesehen am 01.03.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1365-2133 |
| DOI: | 10.1046/j.1365-2133.2000.03852.x |